Bausch + Lomb Corporation (BLCO) is a Healthcare stock trading at $18.01 (as of 2026-09-02), with a market capitalization of $6.43B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Bausch + Lomb sells contact lenses, eye drops, vitamins, dry-eye drugs, and intraocular lenses to eye care doctors and consumers. Most revenue is recurring consumables, with a smaller but faster-growing pharma slice and surgical procedures rounding out the mix.
Contact lens volume (51% of revenue) provides the cash engine, but at 6% operating margin the company is essentially trading high-volume disposables for just enough profit to fund its smaller pharma and surgical lines.
| Vision Care | $0.7B |
| Pharmaceuticals | $0.3B |
| Surgical | $0.2B |
Business quality (Weak): The 6% operating margin and negative 3% ROE place Bausch + Lomb in the weak tier. Growth is present across all segments, but the company has not yet proven it can convert top-line gains into durable shareholder returns.
| Price | $18.01 |
| Market Cap | $6.43B |
| EV / EBITDA | 15.0 |
| Price / Book | 1.00 |
| Price / Sales | 1.21 |
| FCF Yield | -1.0% |
| Revenue (TTM) | $5.10B |
| Net Margin | -7.1% |
| Revenue Growth (YoY) | 9.1% |
| EPS Growth (YoY) | -77.8% |
| FCF Growth (YoY) | -251.9% |
| Altman Z-Score | 0.90 (distress) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 29.8 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Brenton L. Saunders |
| Employees | 13,500 |
| Country | CA |
| IPO Date | 2022-05-06 |
Data as of 2026-09-02.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.